BBOT reports 75% ORR for BBO-8520 combo in 2L+ NSCLC; focuses on KRAS combos

BridgeBio Oncology Therapeutics, Inc.

BBO-8520 + pembrolizumab: 75% ORR at 500 mg QD, 53% across doses in 2L+ G12C inhibitor-experienced NSCLC (N=17).
BBO-8520 monotherapy ORR 63% (26/41), DCR 100% (41/41), no grade 3 liver enzyme elevations in 2L+ G12C inhibitor-naive NSCLC.
$344.1M cash as of June 30, 2026; projected runway into 2028.
Strategic focus on BBO-8520 combo and BBO-11818/BBO-10203 combos in KRAS-mutant CRC and PDAC; data updates Q4 2026 and mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.